Geovax Labs, Inc. · NASDAQ:GOVX
Geovax Labs — Q1 2022 Earnings Presentation
16 slides from Geovax Labs's earnings presentation, May 2, 2022
Slide 1: April 27, 2022
April 27, 2022 NASDAQ: GOVX
Slide 2: Forward Looking Statements
Forward Looking Statements ¢ within the meaning of the Private Certain statements in this presentation may constitute “forward-looking statement: Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstan
Slide 3: GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update
GeoVvax> GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update Company Advancing Phase 2 Clinicat Trials for COVID-19 and Inmuno-Oncologe ATLANTA, GA, April 27, 2022 - GeoVax Labs, Inc. (NasdagCM: GOV), a biotechnology company developing vaccines and immunotherapies again
Slide 4: Accelerating Clinical Development
Accelerating Clinical Development
Slide 5: Strengthen balance sheet goal achieved
Strengthen bal heet to GOAL ae sao Seal are operations AC HIEVED + Exclusive licenses for Gedeptin® (immuno- oncology vaccine) * Exclusive licenses for GEO- CMO04sI (Covid-19 vaccine) Gea + Advanced internal ji * development programs ‘Vache Senving Maran
Slide 6: GeoVax Announces $10 Million Private Placement
Geovax> GeoVax Announces $10 Million Private Placement ATLANTA, GA, January 14,2022 — GeoVax Labs, Inc. (Nasdaq: GOV), a biotechnology company specializing in developing Inuman vaccines and cancer imminotherapies, announced today that it has entered into a securities purchase agreement with a single
Slide 7: Phase 2: Advanced Head and Neck Cancers
Phase 2 : Advanced Head and Neck Cancers + FDA orphan drug status granted + Bring on additional clinical sites to accelerate patient enrollment + Evaluating broader use of Gedeptin in conjunction with Immune Checkpoint Inhibitors (ICIs)
Slide 8: COVID-19 and Variants
COVID-19 and Variants’ ‘ ¢ Achieve clinical development F GOAL status within 12-18 months Licensed GEO-CM04SI, ACHIEVED Covid-19 vaccine; I currently in two Phase 2 Gena trials Vaccine Serv Hamanty
Slide 9: Phase 2: For the Immunocompromised
Phase 2: For the Immunocompromised + Ist trial to specifically evaluate a Covid-19 vaccine in patients with weakened immune systems + Primary vaccine direct comparison of CMO4S1 to the Pfizer/BioNTech mRNA vaccine
Slide 10: GeoVax COVID Vaccine: Phase 2 Booster
Geax COVID Vaccine: Sane GEO-CMO04SI1 Phase 2: Booster + For healthy population fully vaccinated with an mRNA vaccine + Potential for broader and more durable protection versus a 3rd or 4th MRNA dose Wpceee se?
Slide 11: Financial Update
Financial Update "1
Slide 12: Consolidated Statements of Operations Information
GeoVax Labs, Inc. Consolidated Statements of Operations Information (amounts in thousands, except share and per share information) Grant revenues Operating expenses: Research and development General and administrative Loss from operations Other income, net Netloss Loss per common share Three Months
Slide 13: Consolidated Balance Sheet Information
GeoVax Labs, Inc. Consolidated Balance Sheet Information (amounts in thousands, except share information) Mar 34, Dec 31, 2022 2021 Assets Cash and cash equivalents $ 16,258 $ 11,424 Other current assets 379 205 Total current assets 16,637 11,629 Property and other assets, net 218 168 Total assets 7
Slide 14: MORb-Se SICK. a f
Js MORb-Se SICK. a f o CG¢ovax>
Slide 15: 2022 Focus
CGedvax> Vaccines Serving Humanity 2022 Focus. + Successfully advance the three Phase 2 clinical programs in support of Gedeptin® and GEO-CM04s1 + Ensure appropriate resources to support the IND-enabling initiatives of our priority internal programs and operational enhancements and developments
Slide 16: Vaccines Serving Humanity
, Cc Geovex> Vaccines Serving Humanity